Protective Effects of *Millettia Pulchra* Flavonoids on Myocardial Ischemia 
*In Vitro* and *In Vivo*

Jianchun Huang, Xudong Zhang, Feizhang Qin, Yingxin Li, Xiaoqun Duan, Jie Jian, Yongwen Li, Jian Chen, Renbin Huang

*Department of Pharmacology, Guangxi Medical University, Nanning, *MuDanJiang Medical University, MuDanJiang, PR China

**Key Words**
*Millettia pulchra* flavonoids • Myocardial ischemia • Apoptosis • Cardiac hemodynamics

**Abstract**

**Background:** Previous studies have demonstrated that *Millettia pulchra* flavonoids (MPF) exhibit protective effects on myocardial ischemia reperfusion injury (MI/RI) in isolated rat hearts and show anti-oxidative, anti-hypoxic and anti-stress properties. **Methods:** In this study, the cardioprotective effects of MPF on myocardial ischemia and its underlying mechanisms were investigated by a hypoxia/reoxygenation (H/R) injury model *in vitro* and a rat MI/RI model *in vivo*. **Results:** We found that the lactate dehydrogenase (LDH) and inducible nitric oxide synthase (iNOS) activities were decreased in the MPF pretreatment group, whereas the activities of constitutinal nitric oxide synthase (cNOS), total nitric oxide synthase (tNOS), Na\(^+\)-K\(^+\)-ATPase and Ca\(^{2+}\)-Mg\(^{2+}\)-ATPase were significantly increased. In addition, the cardiocytes were denser in the MPF groups than in the control group. The mortality rate and apoptosis rate of cardiocytes were significantly decreased. Furthermore, pretreatment with MPF *in vivo* significantly improved the hemodynamics, decreased malondialdehyde (MDA) abundance, increased the activities of plasma superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and decreased the expression of the Bax protein and ratio Bax/Bc1-2. **Conclusions:** These results suggest that MPF is an attractive protective substance in myocardial ischemia due to its negative effects on heart rate and ionotropy, reduction of myocardial oxidative damage and modulation of gene expression associated with apoptosis.

J. Huang and X. Zhang contributed equally to this work.

**School of Pharmaceutical Sciences, Guangxi Medical University, 22, Shuangyong Road, Nanning, Guangxi 530021 (PR China)**

Tel. +86-771-5339805, Fax +86-771-5338272, E-Mail huangrenbin518@163.com

**Copyright © 2015 S. Karger AG, Basel**
Introduction

Ischemic heart disease is a leading cause of morbidity and mortality worldwide. Myocardial ischemia reperfusion injury (MI/RI) can result in arrhythmia, cardiocyte apoptosis, heart hypofunction and other disorders [1, 2]. The pathophysiology mechanisms behind MI/RI are related to many factors, such as myocardial tissue dysfunction, massive free radical production, changes in hemorheology, increased inflammation, and platelet activation [3, 4]. A substantial amount of evidence from animal experiments and clinical studies supports the idea that reactive oxygen species play a critical role in MI/RI and are a target for therapeutic interventions [5]. Oxygen-derived free radicals and other reactive species are key factors that lead to the oxidative damage of membrane lipids, proteins and carbohydrates, resulting in various alterations of the myocardium, including effects on antioxidant synthesis, inflammation and apoptosis [6-8].

Pharmacological preconditioning is a cardioprotective mechanism induced by drugs or chemicals that can trigger the release of some endogenous protective substances. It is well known that preconditioning by some opioids [9] or potassium channel openers [10] demonstrates protective effects against MI/RI. Recently, increased attention has been focused on traditional Chinese herbal treatments due to their unique decrease of oxidative stress efficacy and limited adverse reactions. For example, flavonoid compounds, which are widely expressed in plants, have important roles in physiological functions. Previous studies have indicated that preconditioning by some flavonoid compounds exhibits cardioprotection against MI/RI [11-13]. Millettia pulchra (Benth.) Kurz var. Laxior (Dunn) Z.Wei (MKL) is a traditional Chinese medicinal herb that is widely distributed in the Guangxi Province of China [14, 15]. Previous studies have demonstrated that extracts of its roots demonstrate anti-hypertensive, anti-oxidative and anti-inflammatory effects [16]. Millettia pulchra flavonoids (MPF) is the major effective ingredient in the MKL root extract [17]. Previous studies have demonstrated that MPF exhibits protective effects on myocardial ischemia reperfusion injury in isolated rat hearts and shows hydroxyl radical and oxygen radical scavenging, anti-hypoxic and anti-stress properties [18-20]. Given this information, we hypothesized that anti-oxidative activities may also be involved in the effect of MPF on myocardial ischemia. The objective of the present study was to determine the anti-apoptosis and anti-myocardial ischemic effects of MPF and to further characterize their mechanisms.

Materials and Methods

Animals

Male and female SD rats weighing 250–280 g and 1–3 d SD neonate rats, SPF, were provided by the Experimental Animal Center of Guangxi Medical University (Guangxi, China). The studies were performed according to the protocols approved by our institutional ethics committee. All rats were housed under controlled conditions at a temperature of 25±2 °C and a relative humidity of 60±10%, with room air changes 12-18 times/hr and a 12-hr light/dark cycle. Food and water were provided ad libitum.

Reagents

The verapamil injection was obtained from Hefeng Pharmaceutical Co., Ltd. (Shanghai, China); Dilthiazem (DIL) tablets were obtained from Shanghai Sine Wanxiang Pharmaceutical Co., Ltd. (Shanghai, China); Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS) and trypsin were purchased from Gibco. (USA); The VFITC/PI apoptosis kit was purchased from Biovision. (USA); Mouse antibodies against Bcl-2 and Bax and corresponding immunohistochemistry reagents were purchased from Santa Cruz Biotechnology. (USA); lactate dehydrogenase (LDH), nitric oxide synthase (NOS), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and Coomassie (Bradford) protein assay kits were acquired from Nanjing Jiancheng Bioengineering Research Institute (Nanjing, China).
Drugs and pharmacological serum preparation

MPF was isolated from the root of MKL as previously described [16] and diluted with 0.5% DMSO at the appropriate concentrations as needed. The MPF medicated serum was prepared at a concentration of 24 mg/L, and the verapamil medicated serum was prepared at a concentration of 10 mg/L, as previously described, with few modifications. Briefly, MPF and Verapamil were injected into the rat duodenum one hour after the instillation; blood was drawn under aseptic conditions, and the serum was separated. After 30 minutes of inactivation at 56 °C, the serum was aliquoted and refrigerated separately from the blood.

Cell culture and treatment

The cardiomyocyte culture system was prepared as previously reported [21, 22]. Briefly, the cells were dispensed into 24-well plates at a density of $3 \times 10^5$ cells/well and grown in DMEM supplemented with 10% heat-treated FBS, 100 U/mL penicillin, 100 U/mL streptomycin and 2 mmol/L glutamine in 5% CO$_2$ at 37 °C. After 72-96 hours, the cells were randomly divided into 6 groups (n=8 plates), as shown in Table 1. The H/R injury model was established with hypoxia for 2 hours, followed by reoxygenation for 4 hours, in all groups except the blank control, as previously described [23]. The cells were incubated in a minimal amount of hypoxia medium and then placed into a hypoxia chamber. The chamber was subsequently flushed for 30 min with a 95% N$_2$/5% CO$_2$ gas mixture, after which the cells in the chamber were returned to a 37 °C incubator for 2 hours. At the end of the hypoxic period, the chamber was removed from the incubator, and the hypoxic medium was rapidly replaced with oxygen-saturated medium. The N$_2$ gas in the chamber was rapidly replaced with O$_2$ gas, after which the cells in the chamber were returned to a 37 °C incubator for 4 hours. Two hours before the hypoxic treatment, the positive drug verapamil medicated serum (10 mg/L) or MPF medicated serum (6, 12, 24 mg/L) was added to the cell culture medium; the H/R model and blank control groups were treated with equal volumes of blank serum only.

Experimental design

Measurement of LDH activity and NOS in vitro. The culture medium was collected after H/R, and the LDH, total nitric oxide synthase (tNOS), inducible nitric oxide synthase(iNOS) and constructional nitric oxide synthase (cNOS) activities were evaluated by ELISA according to the manufacturer’s instructions.

Measurement of Na$^+$-K$^+$-ATPase and Ca$^{2+}$-Mg$^{2+}$-ATPase activities in vitro. After H/R, the cardiomyocytes were digested and centrifuged, and normal saline was added to the layer of cells to generate a cell suspension ($2 \times 10^6 - 3 \times 10^6$ cells/ml). The activities of Na$^+$-K$^+$-ATPase and Ca$^{2+}$-Mg$^{2+}$-ATPase were evaluated by ELISA according to the manufacturer’s instructions. The protein content was evaluated using the Coomassie brilliant blue method, and the activities were expressed as units per milligram of cardiomyocyte protein.

Morphological changes and apoptosis of cardiocytes

Morphological changes of the cardiocytes were detected using acridine orange staining after H/R as previously described [24]. Briefly, the cardiocytes were harvested and fixed with 95% alcohol for 15-30 min, treated for 30 s in 1% acetic acid, stained with $1 \times 10^{-3}$ mmol/L acridine orange for 30 - 60 s, treated for 30 s - 2 min in 0.1 M CaCl$_2$, washed three times with PBS and finally sealed using PBS. To measure the stained cells, four fields per well (100 cells per fields) were randomly selected to quantify the cells that had thick green-staining nuclei by using a fluorescence microscope. The percentages of thick green nuclei were analyzed, and the images were acquired using a digital camera system.

Detection of apoptosis using flow cytometry

Cardiocytes were harvested and washed three times with ice-cold PBS; the cells were stained with Annexin V-FITC and propidium iodide (PI) for 15 min at room temperature in 500 μL binding buffer. Non-
stained cells were considered viable, and cells stained with Annexin V were determined to be in early-stage apoptosis. Surface exposure of phosphatidylserine in apoptotic cells was measured using the Annexin V-FITC apoptosis detection kit according to the manufacturer’s instructions. The results were shown as cell histograms with four quadrants. Additional exposure to PI enabled the differentiation of early apoptotic cells (Annexin V+/PI−, right lower quadrant) from late apoptotic cells (Annexin V+/PI+, right upper quadrant). We also distinguished between normal cells (Annexin V−/PI−, left lower quadrant) and necrotic cells (Annexin V−/PI+, left upper quadrant).

**Rat MI/RI model and treatment**

The rats were randomly placed into 6 groups (n = 8) as shown in Table 1. All animals were anesthetized with sodium pentobarbital (60 mg/kg, i.p.). The MI/RI model was established by ligation of the LAD for 30 min, followed by reperfusion for 60 min, as previously described [25]. The sham group was subjected to identical treatment without LAD artery ligation. During surgery, a subcutaneous electrode was inserted into the rat limb and continuously monitored by electrocardiograms (ECG) in the MI/RI model using the MS4000 biological signal recording and analysis system. The model was considered successfully established when the ST-segment was elevated during myocardial ischemia and decreased by at least 50% during reperfusion [26]. Thirty minutes prior to ligation, the positive drug DIL (5 mg/kg) or MPF (20, 40, 80 mg/kg/day) was administered into the duodenum; the MI/RI model and sham control rats received equal volumes of saline only.

**Measurement of hemodynamic parameters**

During surgery, the MS 4000 system was used to record hemodynamic parameters including heart rate (HR), left ventricular systolic pressure (LVSP), left ventricular diastolic pressure (LVEDP), the largest upstroke velocity of the left ventricular pressure (+dp/dtmax), the largest descendent velocity of the left ventricular pressure (-dp/dtmax), the interval from beginning of left ventricular contraction to +dp/dtmax (t+dp/dtmax) at 0 min (prior to ligation of the LAD), 30 min (30 min after ligation), 60 min (60 min after reperfusion), and r30min (30 min after reperfusion) and r60min (60 min after reperfusion) to evaluate cardiac function.

**Estimations of SOD, GSH-Px and MDA in plasma**

Blood was collected via the abdominal aorta and centrifuged, and the upper plasma layer was isolated to detect the SOD and GSH-Px activities and the MDA content. All of these factors were determined using commercially available kits according to the manufacturer’s instructions.

**Detection of Bcl-2 and Bax expression**

The protein expression levels of Bcl-2 and Bax in myocardial tissues were detected using the appropriate immunohistochemical assay kit according to the manufacturer’s instructions. Sample groupings and treatments were the same as previously described. Briefly, the sections were deparaffinized and microwaved twice for 10 min in 10 mM sodium citrate (pH 6.0). Sections were then incubated in endogenous peroxidase blocking solution for 10 min at room temperature followed by incubation with Bcl-2 and Bax monoclonal antibodies overnight at 4 °C. After washing three times with PBS, the sections were incubated with biotin-conjugated anti-rabbit secondary antibody for 10 min. The sections were then washed three times with PBS, treated with streptavidin-peroxidase for 10 min and washed again with PBS three times. Finally, the specimens were incubated in diaminobenzidine for 5 min, followed by hematoxylin counterstaining. Images from all sections were acquired using a digital camera system. Samples with a brown-stained cytoplasm and no blue-stained nuclei were considered Bcl-2- and Bax-positive cells, respectively. Four fields were randomly selected to quantify the positive cells using a high-power microscope (×400). The data were expressed as the positive expression rate% = cells stained positive/total cardiocytes ×100%.

**Statistical analysis**

Each sample was assayed in triplicate. The results were averaged and expressed as the mean ± SD. One-way ANOVA followed by Bonferroni’s multiple comparison test were used for statistical analysis. P-values less than 0.05 were considered statistically significant.
**Results**

**Effects of MPF on LDH and NOS activities in vitro**

Elevated LDH activity in the culture medium was detected in the H/R model group, and pretreatments with MPF (12, 24 mg/L) and verapamil decreased the LDH activity \( (P<0.05) \) (Fig. 1).

The iNOS activity in the culture medium increased, whereas the cNOS and tNOS activities were decreased in the H/R model group. In addition, pretreatment with MPF (12, 24 mg/L) and verapamil increased the tNOS and cNOS activities \( (P<0.05) \) while reducing the iNOS activity \( (P<0.05) \) compared with the H/R model group (Fig. 2).

**Effects of MPF on Na+-K+-ATPase and Ca\(^{2+}\)-Mg\(^{2+}\)-ATPase in vitro**

The activities of Na\(^+-\)K\(^+-\)ATPase and Ca\(^{2+}\)-Mg\(^{2+}\)-ATPase were significantly decreased in the H/R model group compared with the activities detected in the blank control group \( (P<0.05) \). In contrast, pretreatment with MPF (12, 24 mg/L) and verapamil significantly increased the activities of Na\(^+-\)K\(^+-\)ATPase and Ca\(^{2+}\)-Mg\(^{2+}\)-ATPase (Fig. 3).

**Effects of MPF on morphological changes and cell apoptosis**

Cardiocyte cytoplasm was observed under red fluorescence, and the nuclei were visualized under green fluorescence after staining. Pretreatment with MPF (12, 24 mg/L) and verapamil resulted in denser cardiocytes compared with the H/R model group that were less dense than the blank control group (Fig. 4). In addition, compared with the H/R model group, flow cytometric analysis showed that all dosages of MPF decreased the rate of apoptosis \( (P<0.05) \) in a concentration-dependent manner (Fig. 5A-B).
Effects of MPF on hemodynamic parameters

Compared with the MI/RI model group, pretreatment with MPF (40, 80 mg/kg) and DIL increased HR, LVSP, +dp/dt\textsubscript{max} and -dp/dt\textsubscript{max} (\(P<0.05\)), whereas LVDP, LVEDP and t-dp/dt\textsubscript{max} were significantly decreased (\(P<0.05\)) (Fig. 6).

Effects of MPF on SOD, GSH-Px and MDA in plasma

A significant increase in serum MDA content and a decrease in SOD and GSH-Px activities were detected in the MI/RI model group. Compared with the MI/RI model group, pretreatment with MPF (40, 80 mg/kg) increased the activities of SOD and GSH-Px (\(P<0.05\)) and significantly decreased the MDA content in plasma (\(P<0.05\)) (Fig. 7).

Effects of MPF on the expression of Bc1-2 and Bax proteins

Compared with the MI/RI model group, pretreatment with MPF showed no difference in Bc1-2 protein expression in either group (\(P>0.05\)), but the expression of Bax and the ratio
Huang et al.: Protective Effects of MPF on Myocardial Ischemia

Discussion

Several mechanisms might be involved in the MPF-mediated protective effects on myocardial ischemia injury. NO is an essential modulator of biological systems, including the cardiovascular system, and plays a critical role in cardioprotection. Additionally, cardioprotection is related to the levels of different types of NOS [27, 28]. It is widely accepted that iNOS induces apoptosis but that cNOS inhibits apoptosis [29-31]. In this study, we found that the iNOS activity was higher and the cNOS activity was lower in the H/R model group and that pretreatment with MPF could effectively reverse these changes. These results

Fig. 5. Effect of MPF on cardiocyte apoptosis as detected by flow cytometry with AnnexV-FITC/PI double staining after H/R in vitro. Arrows indicate nonviable apoptotic cells.

of Bax to Bc1-2 proteins were decreased significantly in the MPF (40, 80 mg/kg) and DIL pretreatment groups (P<0.05) (Fig. 8A-D).
indicated that the anti-apoptotic and anti-ischemic effects of MPF were most likely related to the regulation of different NOS subtypes.

LDH is a cytosolic enzyme that is predominantly found in cardiac tissues. Variation in the serum LDH isoenzyme pattern is considered a definitive diagnostic criterion for the assessment of myocardial damage because the rate of LDH appearance and disappearance in the blood indicates the size of the infarction [31]. In the present study, LDH activity was increased in the H/R model group compared with the blank control group, which is supported...
by previous findings [32]. Pretreatment with MPF significantly decreased the LDH activity in the culture medium, suggesting that its membrane stabilized activity.

ATPases play a significant role in the contraction and relaxation of cardiac muscle by maintaining normal ion levels inside myocytes. Na⁺-K⁺-ATPase and Ca²⁺-ATPase are sulfhydryl (–SH) group-containing enzymes and are lipid dependent. A reduction in the activities of these enzymes might be due to enhanced lipid peroxidation by free radicals. Moreover, reduced activities of Na⁺-K⁺-ATPase and Ca²⁺-ATPase may be responsible for the ionic imbalance caused by myocardial ischemia [33]. As shown in Fig. 3, compared with the blank control group, the activities of Na⁺-K⁺-ATPase and Ca²⁺-Mg²⁺-ATPase were lower in the H/R model control group. In addition, the enhanced Ca²⁺-ATPase activity may be due to the activation of adenylate cyclase [34]. Calcium overload in myocardial cells during ischemia activates Ca²⁺-dependent ATPase in the membrane, which depletes high-energy phosphate stores and thereby indirectly inhibits Na⁺ and K⁺ transport and inactivates Na⁺-K⁺-ATPase...
[35]. This process is another important factor leading to myocardial oxidative damage and apoptosis [36-38]. Na⁺-K⁺-ATPase maintains an active potential and myocardial excitation. In this study, we described the activating effect of MPF on ATPase and demonstrated that MPF might inhibit calcium overload by affecting ATPase activity.

We performed in vivo studies to investigate the effects of MPF on hemodynamics in MI/RI rats. In the present study, compared with the MI/RI model group, pretreatment with MPF and DIL increased HR, LVSP, +dp/dt_{max} and -dp/dt_{max}, while LVDP, LVEDP and t-dp/dt_{max} were significantly decreased. These results revealed that MPF increased the ventricular compliance and cardiac diastolic function. In addition, our study indicated that MPF might have a diastolic effect on the peripheral vascular system, which contributed to a reduction in peripheral resistance, a decrease in blood pressure and rescue of cardiac afterload, as previously described [18-20]. However, further studies will be required to elucidate the detailed mechanisms underlying this phenomenon.

MI/RI is characterized by oxidative stress and by changes in the antioxidant enzymes in the heart. There is increased production of oxygen free radicals during MI/RI, which causes unsaturated fat to undergo lipid peroxidation, thereby aggravating myocardial damage [39]. MDA, SOD and GSH-Px levels are classical indices used to evaluate tissue peroxidative injury [40, 41]. A study in dogs has shown that IPC increases the protein expression and activity of myocardial manganese (Mn)–SOD activity not only immediately after IPC but also 24 h after IPC [42]. MDA, which is a lipid peroxidation end product, has been used to assess oxygen free radical-mediated injury of the I/R myocardium [43]. Our results revealed that MPF could increase the plasma SOD and GSH-Px activities and reduce the MDA content. This finding suggested that the enhancement of antioxidase activity and inhibition of peroxidation of free radicals in the myocardium might be, at least partially, involved in the cardioprotective mechanisms of MPF in response to myocardial MI/RI injury.

Additionally, we examined the mechanism of apoptosis induced by MPF by measuring Bc1-2 and Bax protein expression in myocardial tissues (44-46). Our results demonstrated that pretreatment with MPF showed no difference in the expression of Bc1-2 protein in each group but that the expression of Bax protein and the ratio of Bax to Bc1-2 protein were significantly decreased in the MPF pretreatment groups. These results indicate that MPF protected ischemia myocardium, largely by down-regulating the expression of Bax protein and the ratio of Bax protein to Bc1-2.

In conclusion, our study is the first attempt to investigate the cardioprotective effect and potential underlying mechanisms of MPF on myocardial ischemia. Preconditioning with MPF demonstrates a potential protective efficacy on myocardial ischemia via more than one mechanism, including inhibiting myocardial oxidative damage and cardiomyocyte apoptosis and improving heart function. Thus, further investigation of MPF as an anti-myocardial ischemia compound is warranted.

**Abbreviations**

MPF (Millettia pulchra Flavonoids); MKL (Millettia pulchra (Benth.) Kurzvar. Laxior (Dunn) Z. Wei); H/R (hypoxia/ reoxygenation); MI/RI (myocardial ischemia-reperfusion injury); LDH (lactate dehydrogenase); CNOS (constuctional nitric oxide synthase); iNOS (inducible nitric oxide synthase); tNOS (total nitric oxide synthase); LAD (left anterior descending); HR (heart rate); LVSP (left ventricular systolic pressure); LVDP (left ventricular diastolic pressure); LVEDP (left ventricular end-diastolic pressure); +dp/dt_{max} (the largest upstroke velocity of the left ventricular pressure); -dp/dt_{max} (the largest descendent velocity of the left ventricular pressure); t-dp/dt_{max} (the interval from beginning of left ventricular contraction to +dp/dt_{max}); MDA (malondialdehyde); SOD (superoxide dismutase); GSH-Px (glutathione peroxidase); ELISA (enzyme-linked immunosorbent assay); DMEM (Dulbecco’s modified Eagle’s medium); FBS (fetal bovine serum); PBS (phosphate-buffered saline).
Disclosure Statement

The authors declare that there are no conflicts of interest.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81160533, 81360129, 81460205); Guangxi Scientific Research and Technology Development Research Projects (No. 0630002-2A); Guangxi Natural Science Foundation (No. 2013GXNSFAA019175); and fund of Guangxi Key Laboratory of Functional Phytochemicals Research and Utilization (No. FPRU2013-3).

References


